Bristol-Myers Squibb Company (NYSE: BMY) and PDL BioPharma, Inc. (NASDAQ: PDLI) announced an agreement for the global development and commercialization of PDL BioPharma's anti-CS1 antibody, elotuzum
read more » 1 Comment Add this link to...Bury Add to:
| Bookmarks